Tesamorelin: GHRH Analogue Research and Metabolic Applications
Tesamorelin is a synthetic GHRH analogue with a well-established research profile in growth hormone secretion and metabolic biology, including visceral adiposity models.
What Is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that retains the full 44-amino acid sequence of human GHRH with the addition of a trans-3-hexenoic acid group at the N-terminus. This modification improves stability and resistance to proteolytic degradation while preserving full biological activity at the GHRH receptor.
Mechanism of Action
Tesamorelin binds to and activates the GHRH receptor (GHRHR) on pituitary somatotroph cells. This stimulates the synthesis and pulsatile release of endogenous growth hormone, maintaining the physiological pulse characteristics of natural GH secretion.
Key downstream effects studied in research models include:
**GH release**: Tesamorelin produces dose-dependent stimulation of GH secretion from pituitary cells
**IGF-1 elevation**: Increased GH secretion leads to hepatic IGF-1 production, which mediates many of GH's peripheral effects
**Lipid metabolism**: Research has focused on tesamorelin's effects on visceral adipose tissue, with studies demonstrating reductions in trunk fat in preclinical and clinical models
**Metabolic markers**: Studies have examined tesamorelin's influence on triglyceride levels, lipoprotein profiles, and insulin-like growth factor binding proteins
Research Differentiation from GHRP Compounds
Tesamorelin acts exclusively through the GHRH receptor pathway, in contrast to GH secretagogues like ipamorelin or GHRP-6 which act via the ghrelin receptor. This receptor selectivity makes tesamorelin particularly valuable for research specifically focused on the GHRH pathway, allowing clean pharmacological dissection of growth hormone axis components.
Visceral Adiposity Research
One of the more clinically relevant research applications of tesamorelin has been in models of visceral adiposity — excess fat accumulation around abdominal organs. Studies in both animal models and human clinical trials have demonstrated that tesamorelin-induced GH stimulation can selectively reduce visceral fat while largely sparing subcutaneous fat depots. The mechanisms underlying this selective effect remain an active area of research.
Canadian Research Context
Popular Peptides supplies tesamorelin (10mg) as a research-grade compound for Canadian investigators in endocrinology, metabolic biology, and body composition research.
Important Notice
For laboratory and research use only. Not approved for human or veterinary therapeutic application.